Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line

In conclusion, imatinib reversed doxorubicin resistance by decreasing drug efflux in P-gp-overexpressing doxorubicin-resistant canine lymphoma cells. These results suggest that combining doxorubicin, one of the most widely used chemotherapeutic drugs in the treatment of canine lymphoma, with imatinib might potentially overcome doxorubicin resistance in a clinical setting.
Source: The Veterinary Journal - Category: Veterinary Research Source Type: research